Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice

Chen,Yue; Shi,Guang‑Wei; Liang,Zhi‑Man; Sheng,Shu‑Yue; Shi,Yu‑Sheng; Peng,Li; Wang,Ya‑Ping; Wang,Fang; Zhang,Xing‑Mei

doi:10.3892/mmr.2019.10010

Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice

Authors:
- Yue Chen
- Guang‑Wei Shi
- Zhi‑Man Liang
- Shu‑Yue Sheng
- Yu‑Sheng Shi
- Li Peng
- Ya‑Ping Wang
- Fang Wang
- Xing‑Mei Zhang
View Affiliations

Affiliations: Key Laboratory of Psychiatric Disorders of Guangdong Province, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, The First Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: March 6, 2019 https://doi.org/10.3892/mmr.2019.10010
Pages: 3783-3790

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder of the central nervous system that causes severe cognitive impairment. One of the most significant pathological features of AD is the accumulation of β‑amyloid (Aβ) peptide in the brain. Resveratrol (Res) is a polyphenol derived from peanuts, red grapes and other plants, which has received increasing attention due to its neuroprotective features. Tg6799 mice are transgenic mice with five familial AD (FAD) mutations that are also known as 5XFAD mice. The present study aimed to investigate the effects of Res on Tg6799 mice. The transgenic mice were randomly divided into the Res treatment group and the vehicle control group, and were treated with 0.5% Res solution (60 mg/kg) or volume‑matched normal saline, respectively. Treatment was administered by oral gavage daily for 60 consecutive days. Res reduced amyloid plaque formation and the levels of Aβ42, and β‑secretase 1 levels were also significantly decreased. Furthermore, Res was able to reduce the expression of amyloid precursor protein and its cleavage products. The administration of Res to Tg6799 mice also improved their spatial working memory, as measured by the Y‑maze test, and rescued spatial memory deficits, as measured using the Morris water maze test; however, Res did not affect their motor function. In conclusion, this study suggested that Res may reduce Aβ‑induced neuronal damage, thus preventing memory loss.

View Figures

View References

1	McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 34:939–944. 1984. View Article : Google Scholar : PubMed/NCBI
2	Alzheimer's Association: 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 7:208–244. 2011. View Article : Google Scholar : PubMed/NCBI
3	Selkoe DJ and Schenk D: Schenk, Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 43:545–584. 2003. View Article : Google Scholar : PubMed/NCBI
4	Hardy J and Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 297:353–356. 2002. View Article : Google Scholar : PubMed/NCBI
5	Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM and Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 83:4913–4917. 1986. View Article : Google Scholar : PubMed/NCBI
6	Cole SL and Vassar R: BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res. 5:100–120. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lin X, Koelsch G, Wu S, Downs D, Dashti A and Tang J: Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA. 97:1456–1460. 2000. View Article : Google Scholar : PubMed/NCBI
8	Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, et al: Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis. J Neurosci. 27:3639–3649. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA and Vassar R: The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 126:329–352. 2013. View Article : Google Scholar : PubMed/NCBI
10	De Strooper B: Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev. 90:465–494. 2010. View Article : Google Scholar : PubMed/NCBI
11	Robb EL, Page MM, Wiens BE and Stuart JA: Molecular mechanisms of oxidative stress resistance induced by resveratrol: Specific and progressive induction of MnSOD. Biochem Biophys Res Commun. 367:406–412. 2008. View Article : Google Scholar : PubMed/NCBI
12	Baltaci AK, Arslangil D, Mogulkoc R and Patlar S: Effect of resveratrol administration on the element metabolism in the blood and brain tissues of rats subjected to acute swimming exercise. Biol Trace Elem Res. 175:421–427. 2017. View Article : Google Scholar : PubMed/NCBI
13	Baltaci SB, Mogulkoc R and Baltaci AK: Resveratrol and Exercise. Biomed Rep. 5:525–530. 2016. View Article : Google Scholar : PubMed/NCBI
14	Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS and Tessier PM: Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J Biol Chem. 285:24228–24237. 2010. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST and Pasinetti GM: Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 20:2313–2320. 2006. View Article : Google Scholar : PubMed/NCBI
16	Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P and Marambaud P: Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem. 120:461–472. 2012. View Article : Google Scholar : PubMed/NCBI
17	Crandall JP and Barzilai N: Exploring the promise of resveratrol: Where do we go from here? Diabetes. 62:1022–1023. 2013. View Article : Google Scholar : PubMed/NCBI
18	Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al: Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci. 26:10129–10140. 2006. View Article : Google Scholar : PubMed/NCBI
19	The NIH guidelines for the care and use of laboratory animals, . NIH Publication. 85–23, 1985. 1985.
20	Menet MC, Baron S, Taghi M, Diestra R, Dargère D, Laprévote O, Nivet-Antoine V, Beaudeux JL, Bédarida T and Cottart CH: Distribution of trans-resveratrol and its metabolites after acute or sustained administration in mouse heart, brain, and liver. Mol Nutr Food Res. 61:2017. View Article : Google Scholar : PubMed/NCBI
21	Ohno M, Tseng W, Silva AJ and Disterhoft JF: Trace eyeblink conditioning requires the hippocampus but not autophosphorylation of alphaCaMKII in mice. Learn Mem. 12:211–215. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hong YA, Bae SY, Ahn SY, Kim J, Kwon YJ, Jung WY and Ko GJ: Resveratrol ameliorates contrast induced nephropathy through the activation of SIRT1-PGC-1α-Foxo1 signaling in mice. Kidney Blood Press Res. 42:641–653. 2017. View Article : Google Scholar : PubMed/NCBI
23	Area-Gomez E and Schon EA: Alzheimer disease. Adv Exp Med Biol. 997:149–156. 2017. View Article : Google Scholar : PubMed/NCBI
24	Barage SH and Sonawane KD: Amyloid cascade hypothesis: Pathogenesis andtherapeutic strategies in Alzheimer's disease. Neuropeptides. 52:1–18. 2015. View Article : Google Scholar : PubMed/NCBI
25	Andreeva TV, Lukiw WJ and Rogaev EI: Biological basis for amyloidogenesis in Alzheimer's disease. Biochemistry (Mosc). 82:122–139. 2017. View Article : Google Scholar : PubMed/NCBI
26	Billings LM, Oddo S, Green KN, McGaugh JL and LaFerla FM: Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 45:675–688. 2005. View Article : Google Scholar : PubMed/NCBI
27	Selkoe DJ and Schenk D: Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 43:545–584. 2003. View Article : Google Scholar : PubMed/NCBI
28	Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, et al: A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 30:11157–11166. 2010. View Article : Google Scholar : PubMed/NCBI
29	Han YS, Bastianetto S, Dumont Y and Quirion R: Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther. 318:238–245. 2006. View Article : Google Scholar : PubMed/NCBI
30	Gilgun-Sherki Y, Melamed E and Offen D: Oxidative stress induced-neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier. Neuropharmcology. 40:959–975. 2001. View Article : Google Scholar
31	Marambaud P, Zhao H and Davies P: Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 280:37377–37382. 2005. View Article : Google Scholar : PubMed/NCBI
32	Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, Teplow D, Humala N, Cheng A, Percival SS, et al: Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. J Alzheimers Dis. 16:59–72. 2009. View Article : Google Scholar : PubMed/NCBI
33	Jia Y, Wang N and Liu X: Resveratrol and amyloid-beta: Mechanistic insights. Nutrients. 9(pii): E11222017. View Article : Google Scholar : PubMed/NCBI
34	Deng H and Mi MT: Resveratrol attenuates Aβ25–35 caused neurotoxicity by inducing autophagy through the TyrRS-PARP1-SIRT1 signaling pathway. Neurochem Res. 41:2367–2379. 2016. View Article : Google Scholar : PubMed/NCBI
35	Chen CJ, Yu W, Fu YC, Wang X, Li JL and Wang W: Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun. 378:389–393. 2009. View Article : Google Scholar : PubMed/NCBI
36	Jang JH and Surh YJ: Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free RadicBiol Med. 34:1100–1110. 2003. View Article : Google Scholar
37	Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, et al: SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26:3169–3179. 2007. View Article : Google Scholar : PubMed/NCBI
38	Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 127:1109–1122. 2006. View Article : Google Scholar : PubMed/NCBI
39	Porquet D, Griñán-Ferré C, Ferrer I, Camins A, Sanfeliu C, Del Valle J and Pallàs M: Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease. J Alzheimers Dis. 42:1209–1220. 2014. View Article : Google Scholar : PubMed/NCBI
40	Bastianetto S, Ménard C and Quirion R: Neuroprotective action of resveratrol. Biochim Biophys Acta. 1852:1195–1201. 2015. View Article : Google Scholar : PubMed/NCBI
41	Hou Y, Wang K, Wan W, Cheng Y, Pu X and Ye X: Resveratrol provides neuroprotection by regulating the JAK2/STAT3/PI3K/AKT/mTOR pathway after stroke in rats. Genes Dis. 5:245–255. 2018. View Article : Google Scholar : PubMed/NCBI